Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

(Reuters) - Eli ... Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary. The new launches present a big market opportunity as they are some of the most ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

(Reuters) - Eli Lilly plans ... Global demand for Lilly's and Danish rival Novo Nordisk's diabetes and weight-loss drugs has been extraordinary. The new launches present a big market opportunity as ...

Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, launched a new advertising campaign on Friday warning patients about off-brand versions of its treatments, saying “they ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive — and covered an exclusive trip for leaders to attend last summer’s ...

Zeroing in on Eli Lilly, the company is already well established with Zepbound, which should continue to sell briskly as the world waits for a more powerful and efficacious obesity drug to hit the ...